The superficial femoral artery (SFA) is one of the most frequently diseased segments in peripheral arterial disease, and also one of the most mechanically punishing environments for any implanted device. Running from the groin to just above the knee, the SFA bends, twists, and compresses with every step, hip flexion, and knee bend a person makes. Choosing among the available SFA lesion treatment options means weighing not just how well a device opens the artery today, but how it will tolerate years of this repetitive biomechanical stress.
Why Is the SFA So Biomechanically Demanding?
Unlike more fixed vascular territories, the SFA crosses two major joints and passes through the adductor (Hunter's) canal, a relatively confined anatomical tunnel where external compression can add to the mechanical load on any device placed there. Studies of explanted stents have documented flexion, compression, torsion, and elongation forces acting on this segment, which historically caused rigid, balloon-expandable stents to fracture at unacceptable rates. This mechanical reality has shaped virtually every technology developed for SFA disease over recent decades.
Angioplasty Alone: When Is It Enough?
Plain balloon angioplasty, without stenting, remains a reasonable option for some SFA lesions, particularly shorter, non-calcified stenoses where the vessel responds well to dilation without significant elastic recoil or dissection. Its main appeal is leaving no permanent implant behind — an approach sometimes summarized as "leave nothing behind." Its main limitation is a comparatively higher rate of restenosis in many lesion subsets compared with more supported approaches, especially in longer or more complex disease.
Drug-Coated Balloons as an Alternative
Drug-coated balloons (DCBs) deliver an anti-restenotic drug, typically paclitaxel, to the vessel wall during a brief inflation, aiming to reduce the smooth muscle cell proliferation that drives restenosis, without leaving a permanent metal scaffold. DCBs are commonly considered for de novo SFA lesions and for in-stent restenosis. Their main trade-off is that they do not provide mechanical scaffolding, so they are generally reserved for lesions without significant recoil or dissection after angioplasty; if the vessel does not hold open on its own, a stent may still be needed.
Self-Expanding Nitinol Stents for the SFA
When mechanical scaffolding is required, self-expanding nitinol stents have become the standard for the SFA, largely because nitinol's superelastic and fatigue-resistant properties allow it to tolerate the segment's repetitive motion far better than rigid, balloon-expandable designs. These stents apply chronic outward force to maintain patency while flexing with the vessel rather than fighting against it, which materially reduced the fracture rates that plagued earlier peripheral stenting approaches.
Atherectomy for Calcified or Bulky Disease
In heavily calcified SFA lesions, atherectomy — using rotational, directional, or orbital cutting systems to physically debulk plaque — is sometimes used to modify the vessel before balloon or DCB treatment, improving the likelihood that the artery will respond well to subsequent dilation. Atherectomy is generally considered a vessel-preparation adjunct rather than a standalone treatment, since debulking alone does not address the underlying disease process driving restenosis.
How Physicians Choose Among These Options
There is no single correct answer for every SFA lesion; the choice among angioplasty alone, DCB, stenting, and atherectomy depends on lesion length, degree of calcification, prior treatment history, and vessel diameter, assessed through imaging such as duplex ultrasound or angiography. A qualified physician weighs these factors against the specific device's indications and the patient's overall clinical picture, since longer or more complex lesions often require a combination of these tools rather than any single technology in isolation.
INVAMED's Atlas Peripheral Stent System
INVAMED manufactures the Atlas Peripheral Stent System, a self-expanding laser-cut nitinol stent indicated for iliac, SFA, proximal popliteal, and subclavian lesions after balloon angioplasty. According to manufacturer-reported specifications, it is designed for vessel diameters of 5–8 mm and stent lengths from 20–200 mm, delivered through a 6F triaxial system compatible with a 0.035" guidewire. Details are available on the Atlas Peripheral Stent System product page; availability and indications vary by country, so the Instructions for Use (IFU) should always be consulted. The full peripheral arterial disease device category includes complementary balloon and atherectomy technologies used across the SFA treatment pathway.
Can more than one treatment type be used in the same SFA procedure?
Yes, combination strategies are common in clinical practice — for example, atherectomy to debulk calcified plaque followed by a drug-coated balloon, or angioplasty followed by stenting if the vessel does not hold open adequately on its own. The specific combination depends on how the lesion responds during the procedure, as assessed by the treating physician.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.